| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The Journal of Immunology, Vol 137, Issue 9 2952-2955, Copyright © 1986 by American Association of Immunologists
ARTICLES |
G Del Giudice, JA Cooper, J Merino, AS Verdini, A Pessi, AR Togna, HD Engers, G Corradin and PH Lambert
The immunogenicity of a novel synthetic peptide consisting of an average of 40 (Asn-Ala-Asn-Pro) repeats of the circumsporozoite protein of Plasmodium falciparum, (NANP)40, was studied in mice without using any carrier proteins. First, high titers of anti-(NANP)40 antibodies could be obtained after immunization of C57BL/6 mice. These antibodies also reacted with an extract of mosquitoes infected with P. falciparum sporozoites. C57BL/6 nu/nu mice did not produce antibodies against (NANP)40. Secondly, when 14 strains of mice with nine different H-2 haplotypes were immunized with (NANP)40 without carrier, only H-2b mice were found to produce anti-(NANP)40 antibodies, whereas all non-H-2b mice were consistently unresponsive. This response was demonstrated to be I-A-linked by using recombinant and mutant mice. I-Ab [B10.A(5R)] mice produced anti-(NANP)40 antibodies as well as H-2b inbred mice. B6CH-2bm12 I-Ab-mutant mice showed only a very low response. Third, the antibody response against (NANP)40 could be induced in nonresponder mice by immunization with the peptide coupled to a carrier protein. In view of the existence of such an exceptional H-2b restriction in the response to sporozoite synthetic peptides in mice, the triggering of peptide-specific T cell responses in humans receiving sporozoite malaria vaccines might be difficult to achieve.
This article has been cited by other articles:
|
|
 |
|
  J. M. Calvo-Calle, G. A. Oliveira, C. O. Watta, J. Soverow, C. Parra-Lopez, and E. H. Nardin A Linear Peptide Containing Minimal T- and B-Cell Epitopes of Plasmodium falciparum Circumsporozoite Protein Elicits Protection against Transgenic Sporozoite Challenge Infect. Immun., December 1, 2006; 74(12): 6929 - 6939. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Birkett, K. Lyons, A. Schmidt, D. Boyd, G. A. Oliveira, A. Siddique, R. Nussenzweig, J. M. Calvo-Calle, and E. Nardin A Modified Hepatitis B Virus Core Particle Containing Multiple Epitopes of the Plasmodium falciparum Circumsporozoite Protein Provides a Highly Immunogenic Malaria Vaccine in Preclinical Analyses in Rodent and Primate Hosts Infect. Immun., December 1, 2002; 70(12): 6860 - 6870. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Caro-Aguilar, A. Rodriguez, J. M. Calvo-Calle, F. Guzman, P. De la Vega, M. Elkin Patarroyo, M. R. Galinski, and A. Moreno Plasmodium vivax Promiscuous T-Helper Epitopes Defined and Evaluated as Linear Peptide Chimera Immunogens Infect. Immun., July 1, 2002; 70(7): 3479 - 3492. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. N. Fonjungo, I. M. Elhassan, D. R. Cavanagh, T. G. Theander, L. Hviid, C. Roper, D. E. Arnot, and J. S. McBride A Longitudinal Study of Human Antibody Responses to Plasmodium falciparum Rhoptry-Associated Protein 1 in a Region of Seasonal and Unstable Malaria Transmission Infect. Immun., June 1, 1999; 67(6): 2975 - 2985. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Asahi, H. J. Hernandez, and M. J. Stadecker A Novel 62-Kilodalton Egg Antigen from Schistosoma mansoni Induces a Potent CD4+ T Helper Cell Response in the C57BL/6 Mouse Infect. Immun., April 1, 1999; 67(4): 1729 - 1735. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. R. Cavanagh, I. M. Elhassan, C. Roper, V. J. Robinson, H. Giha, A. A. Holder, L. Hviid, T. G. Theander, D. E. Arnot, and J. S. McBride A Longitudinal Study of Type-Specific Antibody Responses to Plasmodium falciparum Merozoite Surface Protein-1 in an Area of Unstable Malaria in Sudan J. Immunol., July 1, 1998; 161(1): 347 - 359. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Etlinger, D Gillessen, H. Lahm, H Matile, H. Schonfeld, and A Trzeciak Use of prior vaccinations for the development of new vaccines Science, July 27, 1990; 249(4967): 423 - 425. [Abstract] [PDF]
|
|
|
|
|
|
E. Nardin, D. Herrington, J Davis, M Levine, D Stuber, B Takacs, P Caspers, P Barr, R Altszuler, P Clavijo, et al. Conserved repetitive epitope recognized by CD4+ clones from a malaria-immunized volunteer Science, December 22, 1989; 246(4937): 1603 - 1606. [Abstract] [PDF]
|
|
|
|
|
|
S. Hoffman, D Isenbarger, G. Long, M Sedegah, A Szarfman, L Waters, M. Hollingdale, P. van der Meide, D. Finbloom, and W. Ballou Sporozoite vaccine induces genetically restricted T cell elimination of malaria from hepatocytes Science, June 2, 1989; 244(4908): 1078 - 1081. [Abstract] [PDF]
|
|
|
|
|
|
G. Lowell, W. Ballou, L. Smith, R. Wirtz, W. Zollinger, and W. Hockmeyer Proteosome-lipopeptide vaccines: enhancement of immunogenicity for malaria CS peptides Science, May 6, 1988; 240(4853): 800 - 802. [Abstract] [PDF]
|
|
|
|
|
|
M. Good, W. Maloy, M. Lunde, H Margalit, J. Cornette, G. Smith, B Moss, L. Miller, and J. Berzofsky Construction of synthetic immunogen: use of new T-helper epitope on malaria circumsporozoite protein Science, February 27, 1987; 235(4792): 1059 - 1062. [Abstract] [PDF]
|
|
|
|
|
|
L. Miller, R. Howard, R Carter, M. Good, V Nussenzweig, and R. Nussenzweig Research toward malaria vaccines Science, December 12, 1986; 234(4782): 1349 - 1356. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
